Related Experiment Video
Updated: Jun 9, 2025
05:30
Controlled Cortical Impact Model for Traumatic Brain Injury
Published on: August 5, 2014
28.5K
Small Molecule Drug C381 Attenuates Brain Vascular Damage Following Repetitive Mild Traumatic Injury
Lulin Li1, Andy Nguyen1, Brian Zhao1
1Palo Alto Veterans Institute for Research, VA Palo Alto Health Care System, Palo Alto, California, USA.
Neurotrauma Reports
|October 28, 2024
Summary
A new drug, C381, shows promise for treating traumatic brain injury (TBI). This TGF-β activator reversed vascular damage and gene expression changes in a mouse model of mild TBI (mTBI), suggesting a potential therapy.
Area of Science:
- Neuroscience
- Vascular Biology
- Pharmacology
Background:
- Traumatic brain injury (TBI) is a major health issue with no effective treatments.
- Vascular dysfunction plays a key role in TBI pathology.
- Transforming growth factor-β (TGF-β) signaling is critical for vascular health and is implicated in neurological disorders.
Purpose of the Study:
- To investigate the therapeutic potential of C381, a novel TGF-β activator, in a mouse model of repetitive mild TBI (mTBI).
- To examine C381's ability to attenuate vascular injury and reverse mTBI-induced gene expression changes.
Main Methods:
- Utilized a mouse model of repetitive mild TBI (mTBI).
- Employed RNA-sequencing (RNA-seq) to analyze gene expression patterns in mTBI.
- Assessed the effect of C381 treatment on gene expression and vascular damage via immunohistochemistry.
Main Results:
- Identified distinct mTBI-related gene expression signatures linked to vascular integrity and endothelial function.
- Demonstrated that C381 treatment reversed these mTBI-induced gene expression changes.
- Showed that C381 attenuated vascular damage in mTBI-affected brain tissue.
Conclusions:
- C381 effectively mitigated vascular injury in a mouse model of mTBI.
- The drug reversed key gene expression alterations associated with mTBI.
- C381 represents a promising novel therapeutic candidate for TBI treatment.
